-
公开(公告)号：EP3022174B1
公开(公告)日：2018-09-05
申请号：EP14744725.4
申请日：2014-07-10
申请人： ALLERGAN, INC.
IPC分类号： C07C275/28 , C07C275/30 , A61K31/17 , A61P27/02 , A61P29/00
CPC分类号： C07K5/06043 , A61K38/05 , C07C275/28 , C07C275/30
摘要： The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
-
2.发明授权METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS 有权用ALPHA-2B肾上腺素受体激动剂激活调节T细胞的方法
公开(公告)号：EP2605771B1
公开(公告)日：2018-04-04
申请号：EP11751717.7
申请日：2011-08-11
申请人： ALLERGAN, INC.
IPC分类号： A61K31/17 , A61K31/4164 , A61K31/4168 , A61K31/4178 , A61K31/421 , A61P1/00 , A61P3/10 , A61P7/06 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/02 , A61P37/00
CPC分类号： A61K31/4164 , A61K31/17 , A61K31/4168 , A61K31/4178 , A61K31/421 , A61K31/4439
摘要： Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
-
3.发明公开PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE 审中-公开包含7-（1H-咪唑-4-基甲基）-5,6,7,8-四氢 - 喹啉的药物组合物
公开(公告)号：EP3184110A1
公开(公告)日：2017-06-28
申请号：EP17156230.9
申请日：2012-11-08
申请人： ALLERGAN, INC.
IPC分类号： A61K31/4709 , A61K9/00 , A61P27/02
摘要： The present invention relates to a method for treating ocular diseases in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及一种治疗有需要的患者的眼部疾病的方法，该方法包括施用治疗有效量的药物组合物，所述药物组合物包含治疗有效量的7-（1H-咪唑-4-基甲基）-5,6 ，7,8-四氢 - 喹啉或其单独的对映体或其互变异构体或其药学上可接受的盐。
-
4.发明公开ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE 有权ESTER-PRODRUGS AUS [3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇十二烷基硫酸甘油酯
公开(公告)号：EP3053576A1
公开(公告)日：2016-08-10
申请号：EP16161922.6
申请日：2011-09-16
申请人： ALLERGAN, INC.
发明人： DIBAS, Mohammed I. , CHOW, Ken , DONELLO, John E. , GARST, Michael E. , GIL, Daniel W. , WANG, Liming
IPC分类号： A61K31/4174 , C07D233/64 , A61P27/06 , A61P17/04
CPC分类号： A61K31/4174 , A61K9/0014 , A61K31/4164 , C07D233/64 , Y10S514/912
摘要： The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
摘要翻译： 本发明涉及降低需要这种治疗的受试者的眼内压的方法，其包括给予治疗有效量的包含[3-（1-（1H-咪唑-4-基） ）乙基）-2-甲基苯基]甲醇，其对映异构体，其互变异构体，含有它们的药物组合物及其作为药物的用途。
-
5.发明公开ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES 审中-公开用于治疗眼内压和眼病通过玻璃体内和给药前房内α-2-肾上腺素能受体激动剂
公开(公告)号：EP2968277A1
公开(公告)日：2016-01-20
申请号：EP14728695.9
申请日：2014-03-12
申请人： ALLERGAN, INC.
IPC分类号： A61K31/4184
CPC分类号： A61K31/4184 , A61K9/0048
摘要： The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline.
摘要翻译： 本发明提供了降低眼内压，其包括施用治疗有效量的包含药物组合物的方法将4-溴-5-（2-咪唑啉-2-基氨基）苯并咪唑，或它们的到患者的受影响的眼睛盐 ，作为单次剂量，worin受影响的眼睛具有眼压小于基线。
-
6.发明公开USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES 审中-公开VERWENDUNG VON AGONISTEN DES FORMYLPEPTIDREZEPTORS 2 ZUR BEHANDLUNG VONAUGENENTZÜNDUNGEN
公开(公告)号：EP2964213A1
公开(公告)日：2016-01-13
申请号：EP14712888.8
申请日：2014-03-04
申请人： ALLERGAN, INC.
IPC分类号： A61K31/17 , A61K9/00 , A61K31/196 , A61K31/4166 , A61K31/42 , A61K31/662 , A61P27/02
摘要： The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
摘要翻译： 本发明涉及在需要这种治疗的受试者中治疗眼部炎性疾病的方法，其包括给予包含治疗有效量的至少一种甲酰基肽受体2激动剂的药物组合物。
-
7.发明公开ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR LOWERING INTRAOCULAR PRESSURE 有权[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇在降低眼内压ESTER前药
公开(公告)号：EP2616068A1
公开(公告)日：2013-07-24
申请号：EP11760962.8
申请日：2011-09-16
申请人： Allergan, Inc.
发明人： DIBAS, Mohammed I. , CHOW, Ken , DONELLO, John E. , GARST, Michael E. , GIL, Daniel W. , WANG, Liming
IPC分类号： A61K31/4174 , A61P27/06
CPC分类号： A61K31/4174 , A61K9/0014 , A61K31/4164 , C07D233/64 , Y10S514/912
摘要： The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
-
8.发明公开ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS 有权酯前药的[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇皮肤疾病和状态的治疗
公开(公告)号：EP2616067A1
公开(公告)日：2013-07-24
申请号：EP11760961.0
申请日：2011-09-16
申请人： Allergan, Inc.
发明人： DIBAS, Mohammed I. , CHOW, Ken , DONELLO, John E. , GARST, Michael E. , GIL, Daniel W. , WANG, Liming
IPC分类号： A61K31/4174 , A61P17/04
CPC分类号： A61K31/4174 , A61K9/0014 , A61K31/4164 , C07D233/64 , Y10S514/912
摘要： The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
-
9.发明公开METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS 有权VERFAHREN ZUR AKTIVIERUNG VON REGULATORISCHEN T-ZELLEN MIT ALPHA-2B-ADRENERGISCHEN REZEPTORAGONISTEN
公开(公告)号：EP2605771A1
公开(公告)日：2013-06-26
申请号：EP11751717.7
申请日：2011-08-11
申请人： Allergan, Inc.
IPC分类号： A61K31/17 , A61K31/4164 , A61K31/4168 , A61K31/4178 , A61K31/421 , A61P1/00 , A61P3/10 , A61P7/06 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/02 , A61P37/00
CPC分类号： A61K31/4164 , A61K31/17 , A61K31/4168 , A61K31/4178 , A61K31/421 , A61K31/4439
摘要： Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
摘要翻译： 本文公开了通过施用α-2受体激动剂上调调节性T细胞并治疗将受益于这种上调的疾病的方法。
-
10.发明公开2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS 审中-公开-2H-吡咯-5-胺衍生物作为α-肾上腺素能受体调节剂
公开(公告)号：EP2486009A1
公开(公告)日：2012-08-15
申请号：EP10765719.9
申请日：2010-10-06
申请人： Allergan, Inc.
发明人： CHOW, Ken , GIL, Daniel W. , DONELLO, John E. , WANG, Liming , CORPUZ, Evelyn G. , FANG, Wenkui K. , SINHA, Santosh C. , DIBAS, Mohammed I.
IPC分类号： C07D207/22 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , A61K31/4025 , A61P9/00 , A61P29/00 , A61P27/06 , A61P17/00
CPC分类号： A61K31/498 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/4184 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4709 , C07D207/22 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , Y10S514/913
摘要： Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.026 秒)
